Related Experiment Videos
[Lung resistance protein analysis in testicular cancer]
László Mándoky1, Lajos Géczi, Zoltán Doleschall
1Országos Onkológiai Intézet, Cytopathologiai osztály, Budapest, Hungary.
Abstract:
Germ cell testicular cancers are well-curable neoplasms, because total remission can be achieved in about 80% of the cases. However, 15-20% of the patients die due to drug resistance (DR). A number of mechanisms of the multidrug resistance phenotype are known, including MDR/P-glycoprotein (P-gp) and the so-called multidrug resistance associated protein (MRP). Lung Resistance Protein (LRP) is an ATP dependent membrane transporter protein associated with MDR. In our present work we studied the expression of LRP in testicular cancers. LRP expression was determined by immunohistochemistry (IH), Western blot (WB) and RT-PCR techniques. Clinical resistance was defined in accordance with the clinical oncologic rules. In 29 (41%) of 70 primary testicular tumours and in 22 (63%) of 35 cases, elevated LRP levels were established by IH and WB, respectively. In the latter 63%, the LRP mRNA levels were elevated as well. Six cases of the 15 seminomas and 23 cases of the nonseminomatous germ cell tumours (NSGCT) proved to be positive. No relationship was demonstrated between LRP expression and the stage of the disease. Despite the LRP positivity of 6 tumour samples, all of the seminomas proved sensitive. Of the 39 sensitive NSGCT, 27 cases were LRP-negative, whereas 11 tumour samples of 16 patients belonging to the resistant group proved LRP-positive (p=0.04). The authors concluded that the expression of LRP is responsible for clinical drug resistance in non-seminomatous testicular cancer patients.
Insights
Lung Resistance Protein (LRP) expression is linked to drug resistance in non-seminomatous testicular cancers. While most testicular cancers are curable, LRP may explain treatment failure in some patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Germ cell testicular cancers are highly curable, yet 15-20% of patients experience treatment failure due to drug resistance.
- Multidrug resistance (MDR) mechanisms, including MDR/P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP), are known contributors to treatment failure.
- Lung Resistance Protein (LRP) is an ATP-dependent membrane transporter protein implicated in MDR.
Purpose:
- To investigate the expression of Lung Resistance Protein (LRP) in testicular tumors.
- To determine the correlation between LRP expression and clinical drug resistance in patients with testicular cancer.
Summary:
- LRP expression was assessed in 70 primary testicular tumors and 35 cases using immunohistochemistry (IH), Western blot (WB), and RT-PCR.
- Elevated LRP levels were detected in 41% of tumors by IH and 63% by WB, with corresponding elevated mRNA levels in the latter group.
- LRP expression was significantly associated with clinical drug resistance in non-seminomatous germ cell tumors (NSGCT) (p=0.04), but not with disease stage or seminoma sensitivity.
Impact:
- The findings suggest that LRP expression is a key factor contributing to clinical drug resistance specifically in non-seminomatous testicular cancer patients.
- Understanding LRP's role may lead to strategies to overcome drug resistance and improve treatment outcomes for this patient population.
- This research highlights LRP as a potential therapeutic target or biomarker for predicting treatment response in testicular cancer.